Ranitidine increases the bioavailability of imbibed alcohol by accelerating gastric emptying

doi:10.1016/0024-3205(95)02316-X

Life Sciences

Volume 58, Issue 6, 5 January 1996, Pages 511-518

https://doi.org/10.1016/0024-3205(95)02316-X Get rights and content

Abstract

To investigate the mechanism of the increase in alcohol bioavailability by ranitidine, we determined by nuclear scan the changes in gastric emptying of a 10% ethanol solution (containing 0.3 g ethanol/kg body weight and 300 μCi of technetium-labeled diethylene triamine pentacetic acid) in 8 normal men, before and after treatment with 300 mg ranitidine orally each evening for 1 week. We compared these changes with those of ethanol bioavailability, calculated by integration of the Michaelis-Menten function over the entire alcohol curves after random i.v. and, on a separate day, oral administration of the same ethanol dose, pre- and post-ranitidine. With ranitidine, we found an acceleration of gastric emptying in 7 of 8 subjects, with 20% shortening of the time to 50% emptying (51.8 ± 4.1 min vs 64.3 ± 3.4, without ranitidine; P < .001 by paired t test). Despite the disappearance (from the stomach) of most of the dose by the end of the blood alcohol curves, only 83 ± 4% reached the systemic blood vs 64 ± 4% without ranitidine (P < .02), most likely because of a shortened exposure of alcohol dehydrogenase to optimal ethanol concentrations. As a result, after oral but not intravenous alcohol administration, ranitidine increased blood alcohol concentrations (29 ± 4 mg/dl vs 22 ± 3, without ranitidine; P < .02), with a corresponding decrease in first pass metabolism of ethanol from 107 ± 16 mg/kg to 47 ± 16 (P < .01).

References (35)

A. Galli et al.
Biochem. Pharmacol.
(1984)
M.C.E. Gwee et al.
Life Sci.
(1986)
J.J. Barboriak et al.
Am. J. Clin. Nutr.
(1970)
C. Dipadova et al.
Gastroenterology
(1987)
C. Dipadova et al.
J.A.M.A.
(1992)
J. Caballería et al.
Digest. Dis. Sci.
(1991)
R.H. Palmer et al.
Am. J. Gastroenterol.
(1991)
G. Pozzato et al.
Scand. J. Clin. Lab. Invest.
(1992)
C.L. Stone et al.
Biochemistry
(1995)
G. Bertaccini et al.
Agents and Actions
(1982)

A. Mizumoto et al.

J. Gastrointest. Motility

(1992)

S. Ueki et al.

J. Pharmacol. Exp. Ther.

(1993)

Y. Ohira et al.

J. Smooth Muscle Res.

(1993)

H. Kaneko et al.

Gastroenterology

(1995)

C. Scarpignato et al.

Agents and Actions

(1982)

R.W. Sherbaniuk et al.

J. Clin. Gastroenterol

(1983)

L.A. Houghton et al.

Aliment. Pharmacol. Ther.

(1987)

Cited by (43)

Ethanol Pharmacokinetics in Neonates and Infants
2014, Current Therapeutic Research - Clinical and Experimental
Citation Excerpt :
Absorption rate is driven primarily by gastric motility, as evidenced by decreases in both Cmax and AUC at 30 minutes with cigarette smoking13 and a reduced Cmax and delayed tmax with aspirin administration.14 Similarly, gastric bypass surgery15 and use of promotility drugs16,17 increase peak blood ethanol levels. Absorption differences can also be linked to the quantity, concentration, and speed at which ethanol is ingested.18
Ethanol has been used for years in neonatal and infant liquid medications, yet the pharmacokinetics, pharmacodynamics, and safety of ethanol in this vulnerable population have not been well characterized. The purpose of this review is to raise awareness of ethanol use as an excipient in neonatal and infant medications and to provide insight, based on the available evidence, into clearance rates of ethanol in babies. We also discuss ethanol pharmacokinetics in adults, theoretical pharmacokinetic changes in neonates and infants as it may apply to ethanol disposition, and case reports involving ethanol exposure in neonates and infants.
This study was a narrative review in which relevant papers were selected using databases and scientific search engines such as PubMed with the key words ethanol, infant, and newborn infant.
It remains unclear what ethanol exposure is safe for neonates and infants. The Food and Drug Administration and American Academy of Pediatrics have both taken action, by either setting limits of ethanol content in over-the-counter medications or by recommending restricted exposure to ethanol-containing pediatric formulations.
Until the short- and long-term health effects of chronic ethanol administration can be further characterized, ethanol-containing medications should be used with caution.
Alcohol-medical drug interactions
2014, Handbook of Clinical Neurology
Concomitant use of alcohol and medications may lead to potentially serious medical conditions. Increasing prescription medication abuse in today's society necessitates a deeper understanding of the mechanisms involved in alcohol-medication interactions in order to help prevent adverse events. Interactions of medications with alcohol result in altered bioavailability of the medication or alcohol (pharmacokinetic interactions) or modification of the effects at receptor or ion channel sites to alter behavioral or physical outcome (pharmacodynamic interactions). The nature of pharmacokinetic or pharmacodynamic interactions involved in alcohol-medication interactions may differ between acute and chronic alcohol use and be influenced by race, gender, or environmental or genetic factors. This review focuses on the mechanisms underlying pharmacokinetic and pharmacodynamic interactions between alcohol and medications and provides examples for such interactions from replicated research studies. In conclusion, further translational research is needed to address several gaps in our current knowledge of alcohol-medication interactions, including those under various pathologic conditions.
Population pharmacokinetics of multiple alcohol intake in humans
2013, Alcohol
Citation Excerpt :
Breath samples have been shown by many investigators to be as precise a PK parameter as venous blood (Fujimiya, Yamaoka, Ohbora, Aki, & Shinagawa, 2002; Norberg et al., 2000; Jones, 1996). Since no reports exist on the population PK of multiple ethanol intake using NONMEM, results of the current study results were compared to those of previous PK studies using Michaelis–Menten kinetics (Table 3) (Amir, Anwar, Baraona, & Lieber, 1996; Gentry et al., 1999; Mumenthaler et al., 2000; Norberg et al., 2000). Both Vmax and Km estimates in a one-compartment model were higher than those in a two-compartment model.
The objective of this study was to determine population-based pharmacokinetics parameters for ethanol following multiple intake and to identify the factors influencing the pharmacokinetics. Three different solutions of alcoholic liquor (ethanol 55.39 ± 0.45 g) with different dissolved oxygen concentrations were administered, and blood alcohol concentration was determined in 59 healthy subjects using a breath analyzer. Samples (n = 2955) were collected at various time points. Population pharmacokinetic modeling was performed to describe the pharmacokinetics of ethanol. The influence of individuals' demography and dissolved oxygen concentration was investigated, and Visual Predictive Check and bootstrapping were conducted for internal evaluation. The developed model was used to perform simulations to visualize the effects of covariates on individuals. A one-compartment model with Michaelis–Menten elimination kinetics described the multiple ethanol intake data. Population pharmacokinetic estimates of V_max and K_m were 3.256 mmol min⁻¹ and 0.8183 mmol L⁻¹, respectively. V_d/F was estimated to be 77.0 L, and K_a was 0.0767 min⁻¹. Body weight, age, and the dissolved oxygen concentration were confirmed to be significant covariates. The mean estimates from the developed population pharmacokinetic model were very similar to those from 500 bootstrap samples, and Visual Predictive Check showed that approximately 94% of the observed data fit well within the 5th–95th percentile. A one-compartment model with nonlinear elimination kinetics for multiple ethanol intake was developed and the significant covariates were determined. The robustness of the developed model was evaluated by bootstrap and Visual Predictive Check. The final model and implanted covariates explained well the variability and underlying mechanism of ethanol PK.
Metabolism of alcohol
2005, Clinics in Liver Disease
Alcohol and the Gastrointestinal Tract
2005, Comprehensive Handbook of Alcohol Related Pathology
Effects of Food and Body Composition on Blood Alcohol Levels
2005, Comprehensive Handbook of Alcohol Related Pathology

View all citing articles on Scopus

View full text

Ranitidine increases the bioavailability of imbibed alcohol by accelerating gastric emptying

Abstract

Biochem. Pharmacol.

Life Sci.

Am. J. Clin. Nutr.

Gastroenterology

J.A.M.A.

Digest. Dis. Sci.

Am. J. Gastroenterol.

Scand. J. Clin. Lab. Invest.

Biochemistry

Agents and Actions

J. Gastrointest. Motility

J. Pharmacol. Exp. Ther.

J. Smooth Muscle Res.

Gastroenterology

Agents and Actions

J. Clin. Gastroenterol

Aliment. Pharmacol. Ther.